Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Gout: HELP
Articles by Fei Yu
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, Fei Yu wrote the following 2 articles about Gout.
 
+ Citations + Abstracts
1 Article Combination Therapies of Diacerein and Febuxostat Inhibit IL-1β Responses and Improve Clinical Symptoms in Patients With Refractory Gout. 2017

Yu, Yi-Kai / Yu, Fei / Ye, Cong / Shen, Gui-Fen / Lei, Xiao-Mei / Zhang, Sheng-Tao / Hu, Shao-Xian. ·Department of Rheumatology, Wuhan Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ·Am J Ther · Pubmed #26035033.

ABSTRACT: There are several therapeutic strategies available for the treatment of an acute gout attack and the prevention of recurrent gout flares, and they include nonsteroid anti-inflammatory drugs. This prospective study was aimed at evaluating the efficiency and safety of diacerein in combination with febuxostat on urate control, global assessments of disease activity, self-monitored gouty acute flare times, inflammatory markers, and clinical symptoms associated with their life quantity in patients with refractory gout. A total of 64 patients with refractory gout were sequentially recruited and prescribed with oral febuxostat alone or febuxostat plus diacerein daily for 12 weeks. The intensity of joint pain, numbers of acute flare, disease activity and the levels of serum amyloid A, mature IL-1β, IL-18, C-reactive protein, and urate in individual subjects were routine analyzed. In comparison with that treatment with febuxostat alone, treatment with both drugs for 12 weeks had a better therapeutic effect on reducing the values of visual analog scales, acute flares, and healthy assessment questionnaire scores in these gout patients. Furthermore, treatment with both drugs also significantly reduced the mean daily dose of etoricoxib and the levels of serum IL-1β and serum amyloid A. There was no significant difference in the frequency of patients with adverse effect between these 2 groups of patients. In conclusion, combination of diacerein and febuxostat had better therapeutic effect on reducing acute gout flares, inflammation, and clinical symptoms in patients with refractory gout.

2 Article Pallidifloside D from Smilax riparia enhanced allopurinol effects in hyperuricemia mice. 2015

Hou, Pi-Yong / Mi, Chao / He, Yi / Zhang, Jun / Wang, Shu-Qing / Yu, Fei / Anderson, Samantha / Zhang, Yan-Wen / Wu, Xiao-Hui. ·Tianjin Key Laboratory on Technologies Enabling Development of Clinical, Therapeutics and Diagnostics, College of Pharmacy, Tianjin Medical University, Tianjin 300070, China. · College of Public Health and Communication, Tianjin Medical University, Tianjin 300070, China. · Tang Center for Herbal Medicine Research, University of Chicago, Chicago, IL 60637, USA. · Tianjin Key Laboratory on Technologies Enabling Development of Clinical, Therapeutics and Diagnostics, College of Pharmacy, Tianjin Medical University, Tianjin 300070, China. Electronic address: zhangyanwen@tijmu.edu.cn. · Tianjin Key Laboratory on Technologies Enabling Development of Clinical, Therapeutics and Diagnostics, College of Pharmacy, Tianjin Medical University, Tianjin 300070, China; Tang Center for Herbal Medicine Research, University of Chicago, Chicago, IL 60637, USA. Electronic address: longhui804@163.com. ·Fitoterapia · Pubmed #26051087.

ABSTRACT: Pallidifloside D, a saponin glycoside constituent from the total saponins of Smilax riparia, had been proved to be effective in hyperuricemic control. Allopurinol is a commonly used medication to treat hyperuricemia and its complications. In this study, we evaluated whether Pallidifloside D could enhance allopurinol's effects by decreasing the serum uric acid level in a hyperuricemic mouse model induced by potassium oxonate. We found that, compared with allopurinol alone, the combination of allopurinol and Pallidifloside D significantly decreased the serum uric acid level and increased the urine uric acid level (both P<0.05), leading to the normalized serum and urine uric acid concentrations. Data on serum, urine creatinine and BUN supported these observations. Our results showed that the synergistic effects of allopurinol combined with Pallidifloside D were linked to the inhibition of both serum and hepatic xanthine oxidase (XOD), the down-regulation of renal mURAT1 and mGLUT9, and the up-regulation of mOAT1. Our data may have a potential value in clinical practice in the treatment of gout and other hyperuricemic conditions.